Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PFCs (perfluorocarbons, PFC), an ideal liquid respiratory media, has special chemical and biological properties, including high solubility of gas, swiftness of carrying and release, low surface tension, high proportion, almost non-absorbing and non-metabolic characteristics in the body. On the basis of the strong animal data suggesting the efficacy of PFC vapor inhalation in models of lung injury, we performed a randomized clinical trial comparing PFC vapor inhalation with conventional mechanical ventilation（CMV）in patients with Acute Lung Injury/Acute Respiratory Distress Syndrome（ALI/ARDS）. The investigators will apply the Invasive Mechanical Ventilation (IMV) to the vaporized perfluorocarbon inhalation, objectively evaluate its curative effect on the acute respiratory distress syndrome, and meanwhile assess the safety of PFC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Dyspnea, Regional Lung Ventilation, and Diaphragmatic Function During de Novo Acute Respiratory Failure

NCT04961437

Acute Respiratory Failure

RECRUITING

Study of a Novel Technique of Mechanical Ventilation in Patients With Severe Acute Respiratory Failure

NCT00637507

Respiratory Distress Syndrome

COMPLETED PHASE2/PHASE3

Early Use of Noninvasive Positive Pressure Ventilation for Intro-pulmonary Acute Lung Injury

NCT01581229

Acute Lung Injury

COMPLETED NA

High Flow Oxygen Therapy in Patients Undergoing Bronchoscopy Under Sedation

NCT04728412

Respiratory Failure Hypercapnic Acidosis

NOT_YET_RECRUITING NA

Early Non-invasive Ventilation Outside the Intensive Care Unit

NCT01572337

Early Acute Respiratory Failure

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on the invasive mechanical ventilation (IMV) treatment of ALI/ARDS, the therapeutic action of vaporized PFC inhalation will be evaluated on the treatment of ALI/ARDS patients, and the safety of vaporized PFC inhalation on the treatment of ALI/ARDS. The Test group will make a timing and fix quantify inhalation of PFC, while the control group will be treated with the inhalation of water for injection. The general condition of patients will be assessed by monitoring their vital signs, hematology testing and APACHE II score, etc. Main outcome measures include the oxygenation index, respiratory mechanics; secondary outcomes include ventilator-free days, 28-day mortality and so on.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome, Adult Acute Lung Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perfluorocarbon

Group Type EXPERIMENTAL

Perfluorocarbon

Intervention Type DRUG

Vaporized PFC Inhalation 100ml/8h for 5 days

Sterile Water for Injection

Group Type PLACEBO_COMPARATOR

Sterile Water for Injection

Intervention Type DRUG

Inhalation of Sterile Water for Injection, 100ml/8h for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Perfluorocarbon

Vaporized PFC Inhalation 100ml/8h for 5 days

Intervention Type DRUG

Sterile Water for Injection

Inhalation of Sterile Water for Injection, 100ml/8h for 5 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-75 years old
* Some clear risk aetiological agents of acute respiratory distress syndrome
* Acute onset, with corresponding clinical manifestations
* PaO2/FiO2 ≤ 300mmHg
* Chest radiograph or chest computerized tomography prompting bilateral pulmonary infiltrate shadow
* pulmonary capillary wedge pressure (PCWP) ≤ 18 mmHg or clinical cardiogenic pulmonary edema can be excluded
* respiratory rate (RR) ≥ 30bpm and (or) respiratory distress
* requiring tracheal intubation or tracheostomy for invasive mechanical ventilation
* or have received invasive mechanical ventilation time ≤ 3 days

Exclusion Criteria

* Age: \< 18 years old or \> 75 years old
* During the early stage of the treatment, the use of mechanical ventilation for more than 3 days other than ALI/ARDS for reasons
* Lung parenchyma and airway surgery carried out within 30 days of the screening period
* Severe arrhythmia and myocardial ischemia after cardiopulmonary resuscitation
* Systolic blood pressure \< 90 mm Hg, and can not maintain its stability with intravenous infusion and vasopressor drugs
* Intubation due to interstitial lung disease (E.g., sarcoidosis, idiopathic pulmonary fibrosis)
* Any active pneumothorax or mediastinal emphysema
* Risk factors leading to the death within 3 months in addition to ALI/ARDS during the screening period (E.g., end-stage cancer)
* Of perfluorocarbons' allergies
* Pregnant, breastfeeding women
* Attending other clinical trial within 30 days of the screening period
* Severe organ dysfunction (Marshall score ≥ 3 or Sequential Organ Failure Assessment（SOFA） score≥ 3, including serious liver and kidney dysfunction, upper gastrointestinal hemorrhage, etc.)
* Acute Physiology and Chronic Health Evaluation（APACHE） II score ≥ 30, high risk of death
* The researchers consider other situations not suitable for the case to participate in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No